Claes et al27 reported a penetrance of 89% in biallelic MYL2 variant carriers or in heterozygous individuals suffering from hypertension or obesity versus 36% in MYL2 variant carriers without additional risk factors. This evidence concerns the gene MYL2 and hypertensive disorder.